TipRanks
Novartis Ag (DE:NOTA)
FRANKFURT:NOTA
Germany Market
NOTA
Novartis
RESEARCH TOOLSreports

Novartis (NOTA) Stock News & Sentiment

27 Followers
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
Premium
TipRanks Newswire
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
6d ago
AZN
NVS
Buy Rating Reiterated on Novartis as Diversified Pipeline Supports Medium-Term Growth; CHF 150 Price Target Unchanged
Premium
Ratings
Buy Rating Reiterated on Novartis as Diversified Pipeline Supports Medium-Term Growth; CHF 150 Price Target Unchanged
7d ago
NVS
Anthropic Builds San Francisco Biology Lab to Advance AI Drug Development
Premium
Market News
Anthropic Builds San Francisco Biology Lab to Advance AI Drug Development
13d ago
BMY
NVO
3 Best Vanguard ETFs for Reliable Dividend Income
Premium
Market News
3 Best Vanguard ETFs for Reliable Dividend Income
20d ago
JPM
NVS
Eli Lilly Stock (LLY) Falls on Competitor Novartis’ Cholesterol Drug Setback
Premium
Market News
Eli Lilly Stock (LLY) Falls on Competitor Novartis’ Cholesterol Drug Setback
23d ago
LLY
NVS
Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss
Premium
Market News
Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss
23d ago
AZN
NVS
Novartis DM1 Trial Setback Offset by Progress in Neuromuscular Pipeline
Premium
Company Announcements
Novartis DM1 Trial Setback Offset by Progress in Neuromuscular Pipeline
23d ago
6K
NVS
More DE:NOTA News >

NOTA News on the Web

Goldman Sachs Remains a Sell on Novartis AG (NOVN)
TipRanks News
Neutral
Piper confident Dyne’s Zeleciment rostudirsen will win January FDA approval
TipRanks News
Bearish
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
Insider Monkey
Bearish
A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team
Insider Monkey
Neutral
HSBC Remains a Buy on Novartis AG (NOVN)
TipRanks News
Neutral
BoomRay Pharma, Novartis Ink Radioligand Therapy Licensing Deal Worth Up To $900 Mln
rttnews
Neutral
Novartis (NVS) Faces Another Pipeline Setback as ALS Drug Fails Mid-Stage Trial
Insider Monkey
Neutral
Novartis' Pipeline In Focus After A Series Of Clinical Setbacks
rttnews
Neutral

News Score - Last 7 Days

Neutral
DE:NOTA
Sector Average
Media Buzz
This Week7 articles
Weekly Average35.75 articles
News Sentiment
This Week0%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:NOTA’s Media Buzz Sentiment?
7 articles about DE:NOTA were published this week. In an average week, 35.75 articles are published.
    What is DE:NOTA’s weekly average amount of articles?
    In an average week, 35.75 articles about DE:NOTA are published.
      What is DE:NOTA’s News Sentiment?
      Currently, no data Available
      Healthcare Stocks that are Trending in the News
      SMMTSummit Therapeutics
      CDNACareDx
      ARGXArgenx Se
      MEOBFMesoblast Limited
      KODKodiak Sciences
      Showing the stocks with the most bullish news sentiment over the past week